What "Maintenance Dose" Means for Retatrutide (and Why It's Unsettled)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Retatrutide does not yet have an established maintenance dose; phase 2 did not test a separate maintenance phase
• The TRIUMPH phase 3 program includes maintenance and dose-reduction sub-studies that should answer this
• Maintenance evidence for semaglutide (STEP 4) and tirzepatide (SURMOUNT-4) shows continued treatment at target dose preserves loss; stopping leads to regain
• By analogy, retatrutide maintenance would likely require continued weekly dosing at or near the target dose
• Retatrutide is investigational; FormBlends does not sell or supply it. Discuss with a licensed clinician

Direct answer

There is no established retatrutide maintenance dose. The phase 2 trial dosed participants at their target (4, 8, or 12 mg) for the full 48 weeks; it did not separate active-loss and maintenance phases. The phase 3 TRIUMPH program is testing maintenance regimens, but results are still pending. By analogy with semaglutide (STEP 4) and tirzepatide (SURMOUNT-4), maintenance would likely require continued weekly dosing at the same target dose. Retatrutide is investigational and not FDA-approved. Discuss with a licensed clinician.

Table of contents

1. What "maintenance" means in obesity pharmacotherapy
2. The phase 2 trial did not have a maintenance phase
3. What SURMOUNT-4 showed for tirzepatide
4. What STEP 4 showed for semaglutide
5. What TRIUMPH phase 3 is testing
6. The dose-reduction question
7. Patient framing: chronic disease, continuous therapy
8. Cost and access realities of indefinite GLP-1 treatment
9. Contrary view: is maintenance always necessary?
10. Decision framework
11. FAQ
12. Sources

What "maintenance" means in obesity pharmacotherapy

The conventional model of obesity treatment splits into two phases. Active loss is the period when weight is decreasing, typically the first 12-18 months of therapy. Maintenance is the indefinite phase that follows, where the goal is preserving loss rather than producing more.

Maintenance dose questions ask three things:

• Does treatment need to continue at all to keep weight off?
• If so, does the same dose used for loss preserve the result, or can the dose be reduced?
• What happens metabolically when treatment stops, and how reversible is that?

For semaglutide and tirzepatide, these questions have been answered by dedicated trials. For retatrutide, they have not been.

The phase 2 trial did not have a maintenance phase

Jastreboff et al. (NEJM 2023) randomized 338 adults to placebo, 1 mg, 4 mg, 8 mg, or 12 mg retatrutide. Participants reached their target dose through titration and stayed at that dose for the remainder of the 48-week study. The trial did not switch participants to a lower maintenance dose after a defined loss period. It did not include an off-treatment follow-up to measure regain.

What the trial did show: weight continued to decline through week 48 in most arms, indicating that 48 weeks was not the plateau of active loss. The slope of weight change was still negative at study end, particularly in the 8 mg and 12 mg arms. This suggests phase 2 captured the active-loss phase only, with no maintenance data to speak of.

What SURMOUNT-4 showed for tirzepatide

SURMOUNT-4 (Aronne et al., JAMA 2024) is the closest analog to a maintenance trial in this drug class. Adults with obesity were treated with tirzepatide for 36 weeks (open-label lead-in) and then randomized to continue tirzepatide or switch to placebo for an additional 52 weeks.

Key findings:

• Continued-treatment group maintained the weight loss achieved during lead-in (mean ~21% from baseline)
• Placebo-switched group regained substantially (mean change from randomization +14%, net loss from baseline ~5%)
• The dose used during the maintenance phase was the same target dose used to reach the loss

The takeaway: tirzepatide maintenance requires continued weekly dosing. Stopping reverses most of the loss within a year.

What STEP 4 showed for semaglutide

STEP 4 (Rubino et al., JAMA 2021) used a similar design with semaglutide. After 20 weeks of open-label semaglutide, participants were randomized to continue semaglutide at 2.4 mg or switch to placebo for an additional 48 weeks.

Continued-semaglutide group: lost an additional 7.9% from randomization. Placebo-switched group: regained 6.9% from randomization. The pattern was qualitatively similar to SURMOUNT-4: continuing the medication preserved or extended weight loss; stopping reversed it.

Both trials used the target dose for maintenance. Neither tested whether a reduced maintenance dose would preserve loss as effectively.

What TRIUMPH phase 3 is testing

The TRIUMPH phase 3 program includes several sub-studies relevant to maintenance:

• Long-duration treatment arms extending past 48 weeks to capture the post-active-loss period
• Dose-reduction sub-studies testing whether maintenance can be achieved at lower doses than were used for loss
• Cardiovascular outcome data that will inform whether maintenance is justified for cardiometabolic risk even in patients who reach goal weight

Public data from TRIUMPH-1 has been released in summary form through Lilly earnings calls and conference presentations but full peer-reviewed publication of maintenance-specific arms is expected through 2026-2027.

The dose-reduction question

For SURMOUNT-4 and STEP 4, the practical question of whether a lower dose preserves loss was not directly tested. The trials compared full dose to placebo. Clinical practice with both tirzepatide and semaglutide has generally kept patients at the target dose during maintenance, although some clinicians titrate down based on side-effect burden or patient preference.

For retatrutide specifically, two hypotheses are circulating in the obesity medicine community:

• The maintenance dose may need to be the target dose, mirroring SURMOUNT-4 and STEP 4 patterns
• The maintenance dose may be reducible because retatrutide's potency creates more pharmacologic headroom than semaglutide; a step down from 12 mg to 4-8 mg might still provide adequate signaling

The TRIUMPH dose-reduction arms should clarify this. Until then, the conservative inference is that retatrutide maintenance would use the same target dose used for active loss.

Patient framing: chronic disease, continuous therapy

The clinical guidelines that govern obesity treatment in 2026 treat obesity as a chronic disease analogous to hypertension or diabetes. The implication for medication use is that effective therapies are continued indefinitely as long as benefits exceed risks, not stopped after a defined weight-loss period.

For retatrutide patients (when and if retatrutide is approved), this would mean entering treatment with the expectation of ongoing use, not a defined treatment course. Patients who frame GLP-1 therapy as "I'll lose the weight and then stop" should be aware that the trial evidence does not support this model.

Cost and access realities of indefinite GLP-1 treatment

Indefinite weekly injection of any GLP-1 medication is expensive at retail. Even compounded versions of approved GLP-1s run several hundred to a thousand dollars per month at typical telehealth pricing. Approved branded products cost more.

For retatrutide specifically, post-approval pricing is unknown. Lilly has not signaled list pricing in public statements. If approved, retatrutide is likely to be priced in line with or above tirzepatide given its more complex mechanism and potential efficacy advantages.

The maintenance-cost reality shapes patient decisions about whether to start GLP-1 therapy at all. A medication that has to be taken indefinitely has a different total-cost profile than one used for a defined course.

Contrary view: is maintenance always necessary?

The dominant evidence supports indefinite maintenance, but two arguments push back.

The set-point reset argument. Some researchers hypothesize that prolonged GLP-1 treatment may produce durable changes in central appetite regulation that persist after treatment ends. The current trial data does not support this; weight regain after stopping is well-documented in both STEP 4 and SURMOUNT-4. But proponents argue that longer treatment durations (3+ years) or specific patient subgroups might show different off-treatment trajectories.

The behavior-internalization argument. Patients who learn new eating patterns during active loss might maintain those patterns without ongoing medication. This is consistent with general behavioral weight-loss literature but the magnitude is generally small. Without medication, even highly motivated patients typically regain a meaningful fraction of lost weight.

The honest position: continuous treatment is the evidence-based default. Stopping treatment is reasonable in specific situations (adverse events, cost barriers, planned pregnancy) but it is not a path to durable weight maintenance for most patients.

Decision framework

If you are evaluating retatrutide: there is not yet a defined maintenance dose. Phase 3 will clarify this. For now, plan as if maintenance would require continued weekly dosing at the target dose.

If you are on FDA-approved tirzepatide or semaglutide: maintenance is generally at the same target dose used to reach the loss. Stopping leads to substantial regain over 6-12 months.

If you are planning a treatment course: GLP-1 medications are best framed as indefinite treatment, not a defined-duration intervention. Cost, side-effect tolerance, and life circumstances over many years all factor in.

Discuss with a licensed clinician.

FAQ

What is a maintenance dose? The dose used after active weight loss to preserve the loss. Not necessarily the same as the dose used to lose weight, though for current GLP-1 evidence they are usually the same.

Does retatrutide have a maintenance dose? Not yet established. Phase 2 did not test a maintenance phase. Phase 3 TRIUMPH is studying it.

What does tirzepatide maintenance look like? SURMOUNT-4 showed continued target-dose dosing preserves loss; stopping leads to regain.

What does semaglutide maintenance look like? STEP 4 showed continued 2.4 mg preserves loss; stopping leads to regain.

Could retatrutide maintenance be at a lower dose? Open research question. TRIUMPH includes dose-reduction arms. No published evidence yet.

Is indefinite GLP-1 use expected? Yes, under current obesity-as-chronic-disease guidelines. The medication preserves loss only while taken.

What happens if I stop? Based on semaglutide and tirzepatide data, substantial regain over 6-12 months. Retatrutide-specific off-treatment data is not yet published.

Related guides

• Retatrutide 4mg Maintenance Dose: What We Know
• Where to Buy Retatrutide in 2026: What "For Research Use Only" Really Means
• TRIUMPH-2 Trial: Retatrutide Long-Term Weight Maintenance
• Retatrutide 28 Percent Weight Loss What That Means
• Retatrutide Maintenance: What Comes After Weight Loss
• The Retatrutide Dose Schedule Used in Phase 2 Trials
• Tool: dosage calculator

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM. 2023.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
6. Rosenstock J et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023.
7. ClinicalTrials.gov NCT05882045 (TRIUMPH-1).
8. American Association of Clinical Endocrinologists Obesity Clinical Practice Guidelines. 2024 update.
9. Endocrine Society Clinical Practice Guideline on Pharmacotherapy of Obesity. 2024 update.
10. Lilly Q4 2024 and Q1 2025 earnings disclosures: TRIUMPH program updates.
11. FDA Drug Approvals Database (no retatrutide approval as of May 2026).

Footer disclaimers

Platform Disclaimer. FormBlends does not sell, supply, or prescribe retatrutide. Retatrutide is investigational and not FDA-approved. This article reflects published clinical-trial evidence and obesity-medicine principles. It is not personal medical advice.

Compounded Medication Notice. Compounded semaglutide and tirzepatide preparations are not FDA-approved drugs. They are prepared by state-licensed 503A pharmacies under USP 797 standards in response to individual prescriptions. Maintenance dosing strategies for compounded GLP-1 medications are determined by clinicians on a case-by-case basis.

Results Disclaimer. Weight-loss and maintenance figures cited reflect group averages in published trials. Individual outcomes vary based on baseline weight, adherence, comorbidities, and other factors. Trial averages should not be read as guarantees of personal outcomes.

Trademark Notice. Retatrutide is an investigational compound owned by Eli Lilly and Company. Mounjaro and Zepbound are registered trademarks of Eli Lilly. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any company referenced above.